Standard BioTools Inc. (LAB)
USD 1.99
(-10.18%)
USD 1.99
(-10.18%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -74.65 Million USD | 60.73% |
| 2022 | -190.09 Million USD | -220.91% |
| 2021 | -59.23 Million USD | -11.73% |
| 2020 | -53.02 Million USD | 18.17% |
| 2019 | -64.79 Million USD | -9.79% |
| 2018 | -59.01 Million USD | 2.51% |
| 2017 | -60.53 Million USD | 20.33% |
| 2016 | -75.98 Million USD | -42.52% |
| 2015 | -53.31 Million USD | -0.92% |
| 2014 | -52.83 Million USD | -233.9% |
| 2013 | -15.82 Million USD | 16.83% |
| 2012 | -19.02 Million USD | 15.34% |
| 2011 | -22.47 Million USD | -32.94% |
| 2010 | -16.9 Million USD | 11.64% |
| 2009 | -19.12 Million USD | 35.16% |
| 2008 | -29.49 Million USD | -15.91% |
| 2007 | -25.45 Million USD | -8.06% |
| 2006 | -23.55 Million USD | 0.0% |
| 2001 | -59.23 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q3 | -26.93 Million USD | 41.08% |
| 2024 Q1 | -32.15 Million USD | -62.61% |
| 2024 Q2 | -45.71 Million USD | -42.17% |
| 2023 Q2 | -17.04 Million USD | -1.17% |
| 2023 Q1 | -16.84 Million USD | 19.2% |
| 2023 FY | -74.65 Million USD | 60.73% |
| 2023 Q4 | -19.77 Million USD | 5.82% |
| 2023 Q3 | -20.99 Million USD | -23.22% |
| 2022 Q4 | -20.84 Million USD | 29.16% |
| 2022 Q2 | -63.53 Million USD | 16.71% |
| 2022 FY | -190.09 Million USD | -220.91% |
| 2022 Q3 | -29.42 Million USD | 53.69% |
| 2022 Q1 | -76.28 Million USD | -709.08% |
| 2021 FY | -59.23 Million USD | -11.73% |
| 2021 Q1 | -18.82 Million USD | -4.41% |
| 2021 Q2 | -17.14 Million USD | 8.92% |
| 2021 Q3 | -13.84 Million USD | 19.25% |
| 2021 Q4 | -9.42 Million USD | 31.89% |
| 2020 Q4 | -18.02 Million USD | -200.48% |
| 2020 Q1 | -15.98 Million USD | -25.98% |
| 2020 FY | -53.02 Million USD | 18.17% |
| 2020 Q2 | -13.01 Million USD | 18.55% |
| 2020 Q3 | -5.99 Million USD | 53.91% |
| 2019 Q2 | -13.75 Million USD | 45.99% |
| 2019 FY | -64.79 Million USD | -9.79% |
| 2019 Q1 | -25.46 Million USD | -72.35% |
| 2019 Q3 | -12.88 Million USD | 6.3% |
| 2019 Q4 | -12.68 Million USD | 1.57% |
| 2018 Q1 | -13.24 Million USD | -26.69% |
| 2018 FY | -59.01 Million USD | 2.51% |
| 2018 Q2 | -16.24 Million USD | -22.6% |
| 2018 Q3 | -14.75 Million USD | 9.18% |
| 2018 Q4 | -14.77 Million USD | -0.17% |
| 2017 FY | -60.53 Million USD | 20.33% |
| 2017 Q4 | -10.45 Million USD | 34.42% |
| 2017 Q3 | -15.94 Million USD | 5.84% |
| 2017 Q2 | -16.93 Million USD | 1.56% |
| 2017 Q1 | -17.2 Million USD | 2.8% |
| 2016 FY | -75.98 Million USD | -42.52% |
| 2016 Q1 | -19.88 Million USD | -54.39% |
| 2016 Q2 | -18.61 Million USD | 6.37% |
| 2016 Q3 | -19.78 Million USD | -6.3% |
| 2016 Q4 | -17.69 Million USD | 10.57% |
| 2015 Q4 | -12.87 Million USD | -38.95% |
| 2015 Q1 | -15.93 Million USD | -45.57% |
| 2015 Q2 | -15.23 Million USD | 4.36% |
| 2015 Q3 | -9.26 Million USD | 39.16% |
| 2015 FY | -53.31 Million USD | -0.92% |
| 2014 Q4 | -10.94 Million USD | 20.64% |
| 2014 FY | -52.83 Million USD | -233.9% |
| 2014 Q3 | -13.79 Million USD | -8.74% |
| 2014 Q2 | -12.68 Million USD | 17.72% |
| 2014 Q1 | -15.41 Million USD | -291.32% |
| 2013 FY | -15.82 Million USD | 16.83% |
| 2013 Q4 | -3.93 Million USD | 8.1% |
| 2013 Q3 | -4.28 Million USD | -5.93% |
| 2013 Q2 | -4.04 Million USD | -13.94% |
| 2013 Q1 | -3.55 Million USD | 1.42% |
| 2012 Q4 | -3.6 Million USD | 13.25% |
| 2012 Q2 | -4.58 Million USD | 31.54% |
| 2012 Q3 | -4.15 Million USD | 9.34% |
| 2012 Q1 | -6.69 Million USD | -93.52% |
| 2012 FY | -19.02 Million USD | 15.34% |
| 2011 FY | -22.47 Million USD | -32.94% |
| 2011 Q3 | -4.48 Million USD | 37.53% |
| 2011 Q1 | -7.33 Million USD | -138.4% |
| 2011 Q4 | -3.45 Million USD | 22.99% |
| 2011 Q2 | -7.18 Million USD | 2.07% |
| 2010 Q4 | -3.07 Million USD | 8.93% |
| 2010 Q3 | -3.38 Million USD | 29.86% |
| 2010 Q2 | -4.81 Million USD | 14.33% |
| 2010 Q1 | -5.62 Million USD | -64.09% |
| 2010 FY | -16.9 Million USD | 11.64% |
| 2009 Q4 | -3.42 Million USD | 0.0% |
| 2009 FY | -19.12 Million USD | 35.16% |
| 2008 FY | -29.49 Million USD | -15.91% |
| 2007 FY | -25.45 Million USD | -8.06% |
| 2006 FY | -23.55 Million USD | 0.0% |
| 2001 Q3 | -13.84 Million USD | 0.0% |
| 2001 FY | -59.23 Million USD | 0.0% |
| 2001 Q4 | -9.42 Million USD | 31.89% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Bionano Genomics, Inc. | -232.49 Million USD | 67.889% |
| Prenetics Global Limited | -62.72 Million USD | -19.023% |
| Star Equity Holdings, Inc. | -1.54 Million USD | -4722.739% |
| CareDx, Inc | -190.28 Million USD | 60.766% |
| Exact Sciences Corporation | -204.14 Million USD | 63.431% |
| Exagen Inc. | -23.68 Million USD | -215.15% |
| Inotiv, Inc. | -105.14 Million USD | 28.994% |
| Guardant Health, Inc. | -479.44 Million USD | 84.429% |
| Biodesix, Inc. | -52.14 Million USD | -43.167% |
| BioNexus Gene Lab Corp. | -2.62 Million USD | -2739.664% |
| Precipio, Inc. | -5.85 Million USD | -1175.517% |
| iSpecimen Inc. | -11.09 Million USD | -572.608% |
| Natera, Inc. | -434.8 Million USD | 82.83% |
| Aspira Women's Health Inc. | -16.69 Million USD | -347.31% |
| 23andMe Holding Co. | -666.7 Million USD | 88.802% |
| Castle Biosciences, Inc. | -57.46 Million USD | -29.913% |
| Personalis, Inc. | -108.29 Million USD | 31.063% |
| Aclaris Therapeutics, Inc. | -88.48 Million USD | 15.625% |
| Applied DNA Sciences, Inc. | -9.94 Million USD | -650.533% |
| OpGen, Inc. | -32.66 Million USD | -128.526% |
| T2 Biosystems, Inc. | -50.07 Million USD | -49.082% |
| Myriad Genetics, Inc. | -112 Million USD | 33.343% |
| ICON Public Limited Company | 612.33 Million USD | 112.192% |
| NeoGenomics, Inc. | -87.96 Million USD | 15.133% |
| Star Equity Holdings, Inc. | -1.54 Million USD | -4722.739% |
| IDEXX Laboratories, Inc. | 845.04 Million USD | 108.835% |
| RadNet, Inc. | 3.04 Million USD | 2552.562% |
| MDxHealth SA | -43.1 Million USD | -73.216% |
| Psychemedics Corporation | -4.15 Million USD | -1697.208% |
| Illumina, Inc. | -1.16 Billion USD | 93.57% |
| Check-Cap Ltd. | -17.56 Million USD | -324.954% |
| Twist Bioscience Corporation | -208.72 Million USD | 64.233% |
| DarioHealth Corp. | -59.42 Million USD | -25.626% |
| Fulgent Genetics, Inc. | -167.82 Million USD | 55.516% |
| Sera Prognostics, Inc. | -36.24 Million USD | -105.993% |
| ENDRA Life Sciences Inc. | -10.06 Million USD | -642.089% |
| OPKO Health, Inc. | -188.86 Million USD | 60.471% |
| Medpace Holdings, Inc. | 282.81 Million USD | 126.398% |
| Neogen Corporation | -9.42 Million USD | -692.442% |
| Intelligent Bio Solutions Inc. | -10.15 Million USD | -635.038% |
| Prenetics Global Limited | -62.72 Million USD | -19.023% |
| Mainz Biomed B.V. | -26.29 Million USD | -183.909% |
| bioAffinity Technologies, Inc. | -7.93 Million USD | -840.606% |
| Trinity Biotech plc | -24.01 Million USD | -210.834% |
| Neuronetics, Inc. | -30.18 Million USD | -147.295% |
| Sotera Health Company | 51.37 Million USD | 245.313% |
| bioAffinity Technologies, Inc. | -7.93 Million USD | -840.606% |